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Objective. This article reports on the test–retest reliability and sensitivity to change of a set of brief dimensional
self-rating questionnaires for social anxiety disorder (SAD-D), specific phobia (SP-D), agoraphobia (AG-D), panic
disorder (PD-D), and generalized anxiety disorder (GAD-D), as well as a general cross-cutting anxiety scale (Cross-D),
which were developed to supplement categorical diagnoses in the Diagnostic and Statistical Manual of Mental
Disorders, 5th edition (DSM-5).
Methods. The German versions of the dimensional anxiety scales were administered to 218 students followed
up approximately 2 weeks later (Study 1) and 55 outpatients (23 with anxiety diagnoses) followed-up 1 year later
(Study 2). Probable diagnostic status in students was determined by the DIA-X/M-CIDI stem screening-questionnaire
(SSQ). In the clinical sample, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnoses
were assessed at Time 1 using the DIA-X/M-CIDI. At Time 2, the patient-version of the Clinical Global Impression—
Improvement scale (CGI-I) was applied to assess change.
Results. Good psychometric properties, including high test–retest reliability, were found for the dimensional scales
except for SP-D. In outpatients, improvement at Time 2 was associated with significant decrease in PD-D, GAD-D,
and Cross-D scores.
Discussion. Major advantages of the scales include that they are brief, concise, and based on a consistent template
to measure the cognitive, physiological, and behavioral symptoms of fear and anxiety. Further replication in larger
samples is needed. Given its modest psychometric properties, SP-D needs refinement.
Conclusion. Increasing evidence from diverse samples suggests clinical utility of the dimensional anxiety scales.
Received 16 May 2013; Accepted 20 August 2013; First published online 8 November 2013
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Objective
In the 5th edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5), categorical
diagnostic criteria for the anxiety disorders are supple-
mented by dimensional measures to provide information
on disorder severity. Previous DSM classifications aimed
to generate almost exclusive and preferably narrow
categorical diagnostic groups and diagnostic subtypes,
but they neglected however symptom heterogeneity
within and co-morbidity across disorder categories.1
Hence, information on disorder severity is desirable
to more precisely map clinical heterogeneity and to
improve diagnostic classification,2 as well as for alloca-
tion to targeted diagnostic procedures, delineation of
treatment strategies, and monitoring of the course of
symptom over time (ie, across treatment).
Disorder severity ratings, assigned by clinicians,
represent a composite of clinician ratings as well as
patient (or patient proxy) ratings. For this reason, a set
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of brief (10-item) patient self-rated scales was developed
by members of and advisors to the DSM-5 Anxiety,
OC Spectrum, Posttraumatic, and Dissociative Disor-
ders work group.* These dimensional anxiety scales are
considered to reliably assess the frequency of physio-
logical, cognitive, and behavioral avoidance symptoms
for social anxiety disorder, specific phobia, agoraphobia,
panic disorder, and generalized anxiety disorder.y All
scales follow a common template but differ by intro-
ductory statements and reference points for the
particular anxiety disorder. In addition to the disorder-
specific anxiety scales, a cross-cutting scale (Cross-D)
that applies to all anxiety disorders was developed
(see LeBeau et al.3 for further details). Given their
briefness and common template, the dimensional scales
are considered to facilitate and supplement diagnostic
assessment, in particular for respondents with more than
one anxiety disorder.
Previous investigations supported the scales’ unidimen-
sionality (internal consistency), convergent and discrimi-
nant validity, and sensitivity to clinical severity for both
the English and German versions in clinical and non-
clinical samples of adults and students,3,4 as well as in a
Dutch sample of children.5 Further, classification perfor-
mance pointed to accurate discrimination between indivi-
duals with versus without a threshold anxiety diagnosis,4
and a cut-off score based on additional assessment of
impairment and distress was found to assist in the discri-
mination between subthreshold and threshold anxiety
disorders.6 Utility of the cross-cutting dimensional anxiety
scale was not clearly supported, as the performance of the
Cross-D was inferior to the disorder-specific dimensional
scales.3,4
Nonetheless, only limited evidence exists with regard to
test–retest reliability of the dimensional anxiety scales. On
the one hand, anxiety disorders tend to naturally wax and
wane,7 which may reduce test–retest reliability of assess-
ment instruments. On the other hand, sensitivity to change
is crucial for clinical assessment8 to allow for both inter-
personal comparisons (ie, Is an anxiety disordered patient
as anxious as another patient with the same anxiety
disorder?) as well as for intrapersonal comparisons (ie, Has
the patient’s level of anxiety decreased after treatment?).
Test–retest reliability has been tentatively established in a
small nonclinical sample of undergraduates.3
Thus, this article reports on 2 studies that assessed
test–retest reliability in a large convenience sample of
students (Study 1) and sensitivity to change in an adult
patient sample that underwent psychological treatment for
anxiety disorders (Study 2) in Germany. Based on results
from previous investigations, we hypothesized high test–
retest reliability for all dimensional scales except for specific
phobia (SP-D) because psychometric properties for this
scale have been consistently lower compared to the other
scales, and have shown the lowest test–retest reliability in
one previous study.3 In the clinical sample, we expect the
scales to prove sensitivity to change as demonstrated by an
association between decrease in the scales and (indepen-
dently measured) mental health improvement.
Methods
Study 1: Participants
Participants of Study 1 were N5218 students (Time 1)
who were enrolled in psychology courses during the
summer session of 2012 at the Technische Universität
Dresden. Students who were age 18 and older were
contacted via email and asked to complete an online
survey. After granting informed consent, participants
provided information on sociodemographics and respon-
ded to the DIA-X/M-CIDI stem screening questionnaire
(SSQ9) to screen for anxiety and other disorder symptoms.
Participants were also asked whether they had ever
contacted a doctor, psychologist, or a psychiatrist because
of any psychological or emotional problems.
Then, the dimensional anxiety scales were presented
along with previously validated measures. Approximately
10 days later (Time 2; mean number of days510.5,
SD52.9, range: 4 to 23 days after Time 1), N5137/218
(62.8%) students completed the anxiety dimensional scales
for a second time (Time 2). Students received course credit
or vouchers for participation. The study was approved
by the Ethics Committee of the Medical Faculty of the
Technische Universität Dresden (No. EK-28022012).
Demographic characteristics and the diagnostic profile
are presented in Table 1. Dropout analyses revealed
differences between participants, who participated at both
times compared to those who were not reassessed with
regard to age, employment status, and branch of study as
well as higher rates of panic disorder and generalized
anxiety disorder in those assessed twice. For gender, family
status, other diagnostic categories, help-seeking, and
scores on dimensional scales, no differences were found
(all p-values. .05; Suppl. Table S1).
Study 2: Participants
Between November 2010 and February 2011 (Time 1), 102
treatment-seeking adults who consulted the university
* Members and advisors of the Anxiety Disorders Subwork Group of the
DSM-5 Anxiety, OC Spectrum, Post-traumatic, and Dissociative Disorder
Work Group are Drs. Gavin Andrews, Susan M. Bögels, Michelle G.
Craske, Katharine A. Phillips, Murray B. Stein, and Hans-Ulrich Wittchen,
and Drs. Lynn Alden, David H. Barlow, Katja Beesdo-Baum, Richard G.
Heimberg, Devon Hinton, Stefan G. Hofmann, Donald F. Klein, Ronald
M. Rapee, and Richard Zinbarg.
y Dimensional scales were also developed for post-traumatic stress
disorder, obsessive compulsive disorder, and separation anxiety disorder,
but these, however, are not the focus of this article.
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outpatient clinic for psychotherapy at the Technische
Universität Dresden (Germany) for mental health problems
completed the dimensional anxiety scales and previously
validated measures along with a standardized diagnostic
interview to establish Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) diagnoses of
mental disorders (DIA-X/M-CIDI9). Previous reports4,6
are based on Time 1 sampling. For this study, from January
to August 2012 (Time 2; mean number of months515.8;
SD52.7, range: 10–20 months after Time 1), N555/102
(53.9%) adults were reassessed with the dimensional and
previously validated anxiety scales, supplemented with
general questions about the current status of mental
and physical health, irrespective of whether they were
allocated to treatment after Time 1 assessment. As shown
in the study flow chart (Figure 1), 40/55 (72.7%)
participants started cognitive behavioral psychotherapy in
the outpatient clinic, and of those, 26 (65.0%) completed
therapy (mean number of sessions528.4; SD514.9;
range: 8–60 sessions) at Time 2, 8 (20.0%) were still in
treatment (mean number of sessions522.0; SD58.5;
range: 7–34 sessions) at Time 2, and 6 (15.0%) dropped
out of treatment (mean number of sessions516.8; SD5
12.1; range: 1–31 sessions). All participants provided
TABLE 1. Sociodemographic characteristics and diagnostic profile of Study 1 and Study 2 participants
Study 1 (student sample) Study 2 (clinical sample)
time 1 (N5 218) time 1 only (N5 81) time 2 (N5 137) time 1 (N5 102) time 1 only (N5 47) time 2 (N5 55)
N % N % N % N % N % N %
Gender
female 177 81.2 66 81.5 111 81.0 70 68.6 31 65.96 39 70.9
male 41 18.8 15 18.5 26 18.9 42 31.4 16 34.04 1 29.1
Age in years; mean(Sd), range 24.39 (5.3), 18–47 25.59 (5.98), 19–47 23.67 (4.7), 18–47 32.0 (11.6), 18–66 3 4.59 (11.09) 18–60 33.7 (12.1), 19–67
18–34 years 209 95.87 75 92.6 134 97.8 70 68.63 33 70.2 37 67.3
35–49 years 9 4.13 6 7.4 3 2.2 21 20.59 9 19.2 12 21.8
50–64 years - - - - - - 10 9.80 5 10.6 5 9.1
651 - - - - - - 1 0.98 0 0.0 1 1.8
Family status
single 135 61.9 45 55.4 90 65.7 77 75.5 7 14.9 18 32.7
married/living with partner 82 37.6 35 43.2 47 34.3 16 15.7 36 76.6 33 60.0
divorced/widowed 1 0.5 1 1.2 0 0.0 9 8.8 4 8.5 4 7.3
Employment-status
student/in education 194 89.4 68 84.0 126 92.7 29 28.4 6 12.8 18 32.7
employed 17 7.8 12 14.8 5 3.7 49 48.0 21 44.7 28 50.9
jobless 2 0.9 1 1.2 1 0.7 9 8.8 11 23.4 3 5.5
other (one missing in study 1) 5 1.8 0 0.0 4 2.9 15 14.7 9 19.2 6 10.9
Branch of study (if student; N5 194)
School of Mathematics and Natural 143 73.7 52 64.1 102 81.0 - - - - - -
Sciences (incl. Psychology)
School of Engineering Sciences 3 1.6 2 2.5 1 0.8 - - - - - -
School of Civil and Environmental Engineering 5 2.6 2 2.5 3 2.4 - - - - - -
School of Humanities and Social Sciences 37 19.1 22 27.2 18 14.3 - - - - - -
Medical School-Medicine 4 2.1 2 2.5 2 1.6 - - - - - -
Others 2 1.0 1 1.2 0 0.0 - - - - - -
Diagnostic profilea
any anxiety disorderb 100 45.9 47 58.0 53 38.7 46 48.0 23 51.06 23f 41.8
social anxiety disorderc 29 13.3 12 14.8 17 12.4 17 16.7 9 17.02 9f 16.4
specific phobiac 18 8.3 9 11.1 9 6.6 19 18.6 10 21.28 9f 16.4
agoraphobiac 10 4.6 4 4.9 6 4.4 15 14.7 10 21.28 5f 9.1
panic disorderd 58 26.6 28 34.6 30 21.9 10 9.8 6 12.77 4f 7.3
generalized anxiety disorderd 56 25.7 27 33.3 29 21.2 17 16.7 8 17.02 9f 16.4
Help-seekinge
yes 63 28.9 23 28.4 97 70.8 - - - - - -
no 155 71.1 58 71.6 40 29.2 - - - - - -
time 1-baseline assessment at time 1; time 1 only – only baseline, but no follow-up assessment; time 2 – assessed at baseline and follow-up
a Study 1: SSQ, positive affirmation of the respective screening question: Study 2: DIA-X/M-CIDI diagnoses in the past 4 weeks
b includes social anxiety disorder; specific phobia, agoraphobia, panic disorder, generalized anxiety disorder
c in the past 12 months
d lifetime
e response to 1 item: ‘Did you ever contact a doctor, a psychological because of psychological or emotional problems?’
f current at Time 1
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written informed consent. Demographic characteri-
stics and the diagnostic profile of Study 2 participants
are presented in Table 1. For Time 1, there were no
significant differences in demographic characteristics or
diagnoses between participants that were reassessed at
Time 2 compared to those who were not reassessed (all
p-values, .05).
Assessments
DSM-5 dimensional anxiety scales
Development and composition of the dimensional
anxiety scales have been described previously.3 Briefly,
a 10-item template was created to assess the frequency
of cognitive symptoms, physical symptoms, and escape
and avoidance behaviors related to fear and anxiety.
This general template was then adapted for social
anxiety disorder (SAD-D), specific phobia (SP-D),
agoraphobia (AG-D), panic disorder (PD-D), and gen-
eralized anxiety disorder (GAD-D) through the use of
different introductory statements and different refer-
ence points throughout the items. Scales were translated
into German language by one of the authors (HUW),
and quality of the translation was ensured via back-
translation by a native English speaker. In the German
version of the scales (available upon request; see LeBeau
et al.3 for the English version of the dimensional scales),
each 10-item dimensional scale was supplemented
by 2 items to assess disorder-related impairment (eg,
for SAD-D: ‘‘I couldn’t take care of important issues
because of fear of social situations’’) and distress (‘‘I felt
stressed and burdened because of my problems related
to social situations’’). All items were anchored to the
past 4 weeks and were rated on a 5-point Likert-type
scale ranging from 0 (‘‘never’’) to 4 (‘‘all of the time’’).
A sum score was created (including distress and
impairment ratings, possible range of scores 0–48).
Unidimensionality and psychometric properties of
the 10- and 12-item versions were comparable, and
scale reliability of both versions was excellent.4 For the
German Cross-D scale (10 items), the item ‘‘needed
help to cope with anxiety’’ was omitted, and instead,
an item assessing distress (‘‘I felt stressed out because
of my fear and anxiety.’’) was used (sum sore range
from 0–40).
Respondents who were not reassessed at Time 2
exhibited similar scores on the dimensional anxiety
scales as compared to participants who participated at
both assessments (Suppl. Table S2).
Previously validated measures
Based on their wide use and the strength of their
psychometric properties, the German versions of several
established self-report scales for each of the anxiety
diagnoses were used to examine convergent and
discriminant validity of the dimensional anxiety scales:
the Brief Symptom Inventory [BSI10; a 53-item scale
assessing symptoms in nine dimensions including
anxiety (panic disorder) and phobia (agoraphobia)];
the Fear Questionnaire [FQ11; assesses how likely an
individual is to avoid certain situations (agoraphobia:
FQ-A, 5 items; social phobia: FQ-Soc, 5 items; blood/
injury-specific phobia subtype: FQ-BI, 5 items)]; the
Mini-SPIN12 (a 3-item screening assessment tool for
generalized social anxiety disorder); and the GAD-713
(a 7-item measure assessing symptoms of general anxiety
disorder). Psychometric properties of these previously
validated measures are recognized to be high.14 The
Patient-Reported Outcome Measurement Information
System—Anxiety scale (PROMIS-Anx15), a 7-item scale
assessing the frequency of anxiety symptoms over the
FIGURE 1. Flow chart of participants through both points of time.
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past week, was included as an established measure of
general anxiety symptoms with reliability above .89 for
the majority of the score distribution.16
Study 1: specific assessments
Previous psychometric analyses of AG-D and SP-D used
only proxy validators to establish validity.4,6 Hence, for
this study, the Panic and Agoraphobia Scale (PAS17) was
additionally used to assess severity within 13 items and
5 subscales of the main factors of panic disorder and
agoraphobia (panic attacks, avoidance, anticipatory
anxiety, disability, and worries about health). Similarly,
the Fear Survey Schedule (FSS-III18,19) was adminis-
tered to assess a larger spectrum of specific fears such
as fears of animals, injury/illness, classical phobias (eg,
being alone), social stimuli, noises, and assorted other
stimuli (eg, falling, insects).
Study 2: specific assessments
To assess change in mental health state in Study 2
participants (patients), the Clinical Global Impression—
Improvement Scale (CGI-I) was used to rate the severity
of symptoms as a result of treatment, ie, the change a
patient made after a treatment initiated.20 The validity
and the sensitivity to change of the CGI-I have been
established.21 The outpatient clinic uses this instrument
both for therapists and also uses an adapted version for
patients to monitor the progress of the treatment. Since
objective CGI-I ratings of the therapists were both not
actual and not available for all participants of Time 2,
the patient-version of CGI-I22 was used to estimate
change. Participants were asked to rate to what extent
their mental or psychosomatic complaints improved or
worsened in comparison to the beginning of treatment
on a 7-point Likert-type scale.
Statistical Analyses
Statistical analyses were performed with the statistical
software package STATA 12,23 except for the confirma-
tory factor analyses, which were conducted using
MPLUS 6.1.24 No adjustment for multiple testing was
applied, because the individual tests were related to
individual hypotheses and adjustment would treat them
as reflecting a global hypothesis, which is questionable
in substantive terms.25
Total scores were calculated for each of the dimen-
sional anxiety scales (SAD-D, SP-D, GAD-D, AG-D,
PD-D; 10- and 12-item versions), for the Cross-D, and
also for the validated scales (Mini-SPIN, FQ, GAD-7,
PAS, FSS-III, FPROMIS-Anx). The BSI was scored
using means.
For Study 1, psychometric properties of the specific
dimensional anxiety scales and the Cross-D were
determined in concordance with previous analyses.4,6
Briefly, (uni-)dimensionality of the dimensional anxiety
scales was examined with confirmatory factor analysis.26
Adequate model fit was evaluated by the fit indices
as suggested by Hu and Bentler.27 Internal consistency
was determined according to Cronbach’s alpha coeffi-
cient. Convergent and discriminant validity of the
dimensional scales was analyzed with Pearson correla-
tions between the dimensional scales and each of the
validated scales. The test for correlated correlation
coefficients28 was used for comparing the correlation
coefficients for conceptually similar measures (eg, SAD-D
and Social Phobia Scale of the FSS) to conceptually
different measures (eg, SAD-D and PAS, or SAD-D and
GAD-7). For the Cross-D, Pearson correlations between
the Cross-D total score and the total scores on each of
the dimensional scales were calculated. To establish
classification performance, the area under the curve
(AUC) was calculated to determine the accuracy at
which each dimensional scale differentiates between
affected and non-affected participants, and among those
with and without help-seeking.
Test–retest reliability (Study 1) was examined using
intraclass correlational coefficients (ICCs) between the
total score on each of the 5 disorder-specific dimen-
sional scales and the Cross-D at Time 1 with the total
score on each scale at Time 2. Being consistent with
standards in the field and LeBeau et al.,3 test–retest
reliability needed to exceed .70.
As Study 2 builds on the sample of Beesdo-Baum
et al.,4 results on psychometric properties of the dimen-
sional scales will not be repeated here. The primary aim
of reassessment of the clinical sample was to examine
the scales’ sensitivity to change (Study 2). Therefore,
linear regression analyses were computed with CGI-I as
independent variable and the change in scores of the
dimensional anxiety scales (Time 2minus Time 1) as
the dependent variable. Since Beesdo-Baum et al.4
demonstrated that patients with DSM-IV–defined spe-
cific diagnoses scored higher on the corresponding
disorder-specific scale, the regression analyses for the
dimensional scales were computed for the participants
with the respective diagnoses (as assessed at Time 1).
Due to the non-normal distribution of the dimensional
scores (Time 1) and previously validated measures
(Time 2; tested with the Shapiro–Wilk test) and the
small sample size, the standard errors and 95%
confidence intervals for parameter estimates of the
linear regression analyses were estimated by bootstrap-
ping for bias accelerated.29
Welch’s test for continuously distributed data and
chi-square statistics for categorical data were used to
analyze differences between participants who were
assessed both times and those who dropped out after
the first assessment in both Studies 1 and 2.30
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Results
Because of similar results and in order to be consistent
with previous publications,3,4 only results of the 10-item
versions of the dimensional anxiety scales will be
reported (results of the 12-item versions were similar
and are available upon request). Descriptives for the
dimensional anxiety scales (10-items) and Cross-D for
Study 1 and Study 2 are presented in Table 2. There
were no significant differences in dimensional scale
scores between participants of both time points com-
pared to those who were only assessed at Time 1.
Study 1: confirmation of psychometric properties
Unidimensionality was established for each dimensional
scale (Table 3), and internal consistency of each of the
scales ranged between .87 for GAD-D and .91 for AG-D,
and was .90 for Cross-D.
Convergent validity was demonstrated by higher
correlations between dimensional anxiety scales and
corresponding previously validated anxiety scales as
compared to correlations with noncorresponding
measures (Table 4). The corresponding correlation
coefficients were significantly higher for SAD-D and
TABLE 2. Descriptives for the dimensional anxiety scales (10-items) and Cross-D (9 items)
Study 1 (student sample) Study 2 (clinical sample)
time 1 (N5 218) time 1 only (N5 81) time 2 (N5 137) time 1 (N5 102) time 1 only (N5 47) time 2 (N5 55)
M SD M SD M SD M SD M SD M SD
SAD-D 4.7 4.7 5.0 5.8 4.8 5.6 11.3 9.3 10.3 9.6 5.8 6.9
SP-D 3.2 5.2 4.1 6.4 2.8 5.1 8.2 9.0 9.3 10.9 4.2 7.5
AG-D 2.0 4.5 2.7 5.9 1.6 4.3 6.9 9.4 8.8 10.8 3.7 7.8
PD-D 2.0 4.0 2.3 5.0 2.2 4.1 7.6 9.3 9.3 10.9 4.2 7.6
GAD-D 5.3 5.3 6.1 5.6 4.9 5.8 11.8 9.9 12.5 10.3 7.2 7.8
Cross-D 6.1 5.8 6.8 6.0 5.7 6.3 14.0 9.2 14.2 10.1 8.1 8.5
M mean, SD standard deviation
SAD social anxiety disorder, SP specific phobia, AG agoraphobia, PD panic disorder, GAD generalized anxiety disorder, Cross-D cross-cutting dimensional scale time 1 -
baseline assessment at time 1; time 1 only - only baseline, but no follow-up assessment; time 2 - assessed at baseline and follow-up
TABLE 3. Results of Confirmatory Factor Analyses for dimensionality (one) and scale reliability in Study 1 (N 5 218 students)
Scale Parameter 10-item scale 12-item scale
Chi2 (df); p Value 67.7 (34); p, .001 101.5 (51); p, .001
SAD-D CFI/TLI/SRMR 0.97/0.96/0.04 0.97/0.95/0.04
reliability1 0.89 0.92
Chi2 (df); p Value 127.1 (33); p, .001 206.2 (51); p, .001
SP-D CFI/TLI/SRMR 0.92/0.88/0.05 0.89/0.86/0.06
reliability1 0.90 0.91
Chi2 (df); p Value 193.7 (32); p, .001 300.6 (51); p, .001
AG-D CFI/TLI/SRMR 0.89/0.85/0.07 0.87/0.83/0.07
reliability1 0.91 0.93
Chi2 (df); p Value 137.2 (31); p, .001 229.9 (49); p, .001
PD-D CFI/TLI/SRMR 0.92/0.88/0.05 0.90/0.87/0.05
reliability1 0.88 0.90
Chi2 (df); p Value 96.19 (33); p, .001 167.8 (52); p, .001
GAD-D CFI/TLI/SRMR 0.93/0.90/0.05 0.91 0.88/0.05
reliability1 0.87 0.90
Chi2 (df); p Value 96.45 (34); p, .001
Cross-D CFI/TLI/SRMR 0.94/0.92/0.05
reliability1 0.90
SRMR5 0 indicates perfect fit; SRMR5 0.05 good fit and SRMR5 0.08 is considered adequate fit CFI (Comparative Fit Index) and TLI (Tucker-Lewis Index; Relative
Noncentrality Index); values close to 1 indicate good fit, values around 0.9 indicate acceptable fit
1 Cronbach’s Alpha
SAD social anxiety disorder, SP specific phobia, AG agoraphobia, PD panic disorder, GAD generalized anxiety disorder, Cross-D cross-cutting dimensional scale
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TABLE 4. Convergent and discriminant validity of 10-item dimensional anxiety scales in Study 1 (N 5 218 students)
Previously Validated Scales
Mini-SPIN FQ-Subscales BSI-Subscales PAS FSS-III-Subscales GAD-7
Social Phobia Blood-Injury Phobia Agoraphobia Phobia (agoraphobia) Anxiety (panic) Social Phobia Specific Phobia Agoraphobia
Dimensional Anxiety Scales Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2 Corr1 P Value2
SAD-D .69 (,.001) (ref.) .65 (,.001) .152 .16 (.016) ,.001 .41 (,.001) ,.001 .56 (,.001) .050 .59 (,.001) .023 .41 (,.001) ,.001 .67 (,.001) .278 .19 (.005) ,.001 1.54 (,.001) .020 1.60 (,.001) .030
SAD-D .69 (,.001) .152 .65 (,.001) (ref.) .16 (.016) ,.001 .41 (,.001) ,.001 .56 (,.001) .022 .59 (,.001) .092 .41 (,.001) ,.001 .67 (,.001) .352 .19 (.005) ,.001 .54 (,.001) .05 .60 (,.001) .127
SAD-D .69 (,.001) .278 .65 (,.001) .352 .16 (.016) ,.001 .41 (,.001) ,.001 .56 (,.001) .012 .59 (,.001) .037 .41 (,.001) ,.001 .67 (,.001) (ref.) .19 (.005) ,.001 .54 (,.001) .020 .60 (,.001) .048
SP-D .31 (,.001) .392 .33 (,.001) .476 .33 (,.001) (ref.) .22 (,.001) .067 .37 (,.001) .291 .44 (,.001) .058 .37 (,.001) .289 .40 (,.001) .168 .33 (,.001) .484 .48 (,.001) .013 .36 (,.001) .352
SP-D .31 (,.001) .398 .33 (,.001) .463 .33 (,.001) .484 .22 (,.001) .073 .37 (,.001) .280 .44 (,.001) .048 .37 (,.001) .286 .40 (,.001) .109 .33 (,.001) (ref.) .48 (,.001) .006 .36 (,.001) .337
AG-D .42 (,.001) .143 .43 (,.001) .140 .16 (.018) ,.001 .49 (,.001) (ref.) .67 (,.001) ,.001 .51 (,.001) .331 .61 (,.001) .016 .42 (,.001) .135 .17 (.012) ,.001 .66 (,.001) ,.001 .44 (,.001) .224
.42 (,.001) ,.001 .43 (,.001) ,.001 _.16 (.018) ,.001 .49 (,.001) ,.001 .67 (,.001) (ref.) .51 (,.001) ,.001 .61 (,.001) .103 .42 (,.001) ,.001 _.17 (.012) ,.001 .66 (,.001) .398 .44 (,.001) ,.001
.42 (,.001) .020 .43 (,.001) .020 .16 (.018) ,.001 .49 (,.001) .016 .67 (,.001) .103 .51 (,.001) .020 .61 (,.001) (ref.) .42 (,.001) .010 _.17 (.012) ,.001 .66 (,.001) .139 .44 (,.001) .020
.42 (,.001) ,.001 .43 (,.001) ,.001 .16 (.018) ,.001 .49 (,.001) ,.001 .67 (,.001) .398 .51 (,.001) ,.001 .61 (,.001) .139 .42 (,.001) ,.001 ‘.17 (.012) ,.001 .66 (,.001) (ref.) .44 (,.001) ,.001
PD-D .34 (,.001) ,.001 .38 (,.001) ,.001 .30 (,.001) ,.001 .42 (,.001) ,.001 .50 (,.001) .003 .63 (,.001) (ref.) .64 (,.001) .418 .42 (,.001) ,.001 .24 (,.001) ,.001 .58 (,.001) .141 .48 (,.001) ,.001
.34 (,.001) ,.001 .38 (,.001) ,.001 .30 (,.001) ,.001 .42 (,.001) ,.001 .50 (,.001) .040 .63 (,.001) .418 .64 (,.001) (ref.) .42 (,.001) ,.001 .24 (,.001) ,.001 .58 (,.001) .121 .48 (,.001) .003
GAD-D .45 (..001) ,.001 .43 (,.001) ,.001 .30 (,.001) ,.001 .37 (,.001) ,.001 .51 (,.001) ,.001 .67 (,.001) .015 .51 (,.001) ,.001 .57 (,.001) ,.001 .32 (,.001) ,.001 .56 (,.001) ,.001 .73 (,.001) ref
ref.5 reference correlation for test of correlation coefficient, printed in bold
1 Correlation (significance level)
2 P Value for comparing correlation coefficient between a dependent variable (ref.) and a set of independent variables in the row
p# .05
SAD social anxiety disorder, SP specific phobia, AG agoraphobia, PD panic disorder, GAD generalized anxiety disorder
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GAD-D (p, .001). The corresponding correlations
between PD-D and BSI-Anxiety and between PD-D
and PAS were similar to the noncorresponding corre-
lation between PD-D and FSS-Agoraphobia (p5 .121,
p5 .141). Further, the corresponding correlation between
AG-D and FQ-Agoraphobia was mostly similar to their
noncorresponding correlations (BSI-Anxiety: p5 .331,
Mini-SPIN: p5 .143, FQ-Social Phobia: p5 .140, FSS-
Social Phobia: p5 .135, GAD-7: p5 .224). For SP-D,
where the corresponding measures cover only 1 (FQ-
Blood/Injury Phobia: blood/injury) or 2 (FSS-Specific
Phobia: animal and blood/injury) disorder subtypes,
moderate correlation coefficients between SP-D and
both of the corresponding measures (r5 .33, r5 .33)
were observed. Corresponding correlations for the
specific dimensional scales and PROMIS-Anx were
moderate to high (r range from .53 for SP-D to .84 for
GAD; r5 .78 for Cross-D; all p-values, .001), and
similarly, they were moderate to high for the specific
dimensional scales and Cross-D (r range from .53 for
SP-D to .84 for PD-D; r5 .77 for PROMIS-Anx; all
p-values, .001).
As shown in Table 5, participants who positively
affirmed the specific SSQ-stem question with and
without help-seeking reported higher scores on the
specific dimensional anxiety scales and the Cross-D
than respondents without an indication for an anxiety
disorder (p, .05). Classification performance was good
to high for the dimensional anxiety scales and the
Cross-D with AUC between .76 for Cross-D and .89 for
SAD-D. Of note, among positively screened partici-
pants, scores were apparently higher for those with
help-seeking than for those without, though these
differences were only statistically firm for Cross-D
(p, .05). Here, AUC was low to moderate, ranging
between .53 for SP-D to .67 for Cross-D.
Study 1: test–retest reliability
At Time 2, N5137/218 participants were included in
the test–retest analyses. ICCs were calculated between
the dimensional anxiety scales completed at Time 1 and
Time 2: With the exception of SP-D (ICC5 .66), strong
test–retest reliability for the dimensional anxiety scales
(ICCs range from .77 to .81) and the Cross-D (ICC5 .85)
could be demonstrated. No significant differences
emerged for test–retest correlations between partici-
pants who completed second time assessment within
the allotted time frame and those who did not (Suppl.
Table S3).
Study 2: sensitivity to change
Regression analyses based on 55/102 patients who
participated at Time 1 and Time 2 assessments revealed
that the greater the improvement in CGI-I, the higher
the improvement (lower score) in the mean difference
score of the dimensional anxiety scales (Time 2minus
Time 1; Figures 2a–2f). Specifically, for participants
with any anxiety disorder at Time 1, one point more on
CGI-I (improved) resulted in 2.74 points less (mean
difference, p, .05) on Cross-D at Time 2.
Discussion
A set of brief dimensional self-rating questionnaires
for social anxiety disorder, specific phobia, agoraphobia,
panic disorder, and generalized anxiety disorder, as well
as a general cross-cutting dimensional anxiety scale
were developed by the Anxiety Disorders Subgroup of
the DSM-5 Anxiety, OC Spectrum, Posttraumatic, and
Dissociative Disorder Work Group in order to support
the categorical approach of diagnostic classification of
TABLE 5. Classification performance of the dimensional anxiety and Cross-D scales in Study 1 (N 5 218 students)
Group 1 Group 2 Group 1 vs Group 2 Group 3 Group 4 Group 3 vs Group 4
SSQ-itema,b negatively
affirmed
SSQ-itema,b positively
affirmed
Comparisonc and
Classification
SSQ-itema,b positively affirmed
WITHOUT help-seeking
SSQ-itema,b positively affirmed
WITH help-seeking
Comparisonc and
Classification
N M SD N M SD P AUC N M SD N M SD p AUC
SAD-D 189 3.4 3.7 29 12.7 7.8 ,.001 0.89 13 10.2 5.3 16 14.8 9.1 .095 0.64
SP-D 200 2.7 4.7 18 8.9 7.0 .001 0.79 11 8.1 4.7 7 10.3 9.8 .596 0.53
AG-D 208 1.4 3.4 10 14.1 7.8 ,.001 0.86 4 11.8 7.8 6 15.7 8.1 .446 0.73
PD-D 160 0.8 1.7 58 5.2 6.2 ,.001 0.77 32 4.2 4.9 26 6.5 7.5 .183 0.59
GAD-D 162 3.9 3.9 56 9.2 6.8 ,.001 0.73 26 7.7 6.6 30 10.5 6.8 .129 0.61
Cross-D 118 3.7 3.9 100 8.9 6.4 ,.001 0.76 59 7.2 5.5 41 11.3 7.0 .002 0.68
N number, M mean, SD standard deviation
a based on positive affirmation of the SSQ-screening question regarding the corresponding anxiety disorder
b for Cross-D: based on positive affirmation of any of the SSQ-screening questions for the anxiety disorders
c Comparisons are based on univariate regressions, p, .05; AUC area under the curve
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DSM-5 by a dimensional assessment. Our results from
study 1 replicate and expand previous findings3,4,6 on the
clinical utility and good psychometric properties of the
dimensional scales to a larger convenience sample of
young adults. Of note, all scales were administered online
(Web-based) to facilitate data collection and analyses.
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FIGURE 2. Scatterplots of the relation between the difference of scores on the dimensional anxiety scales (Time 2 – Time 1) and the Clinical Global
Impression—Improvement Scale (CGI-I) from linear regression analyses. (a) Relation between difference of the SAD-D scores (Time 2 – Time 1) and CGI-I
(Beta5 .–1.9 [–4.6 to 0.8], p5 .166); (b) relation between differences of the SP-D scores (Time 2 – Time 1) and CGI-I (Beta5 –6.1 [13.4 to 1.3],
p5 .106); (c) relation between the difference of AG-D scores (Time 2 – Time 1) and CGI-I (Beta5 .–5.2 [–13.3 to 2.9], p5 .206); (d) relation between
the difference of PD-D scores (Time 2 – Time 1) and CGI-I (Beta5 –4.7 [–5.9 to –3.4], p, .001); (e) relation between the difference of GAD-D scores
(Time 2 – Time 1) and CGI-I (Beta5 –2.4 [–4.3 to –0.5.], p5 .014); (f) relation between the difference of Cross-D scores (Time 2 – Time 1) and CGI-I
(Beta5 –2.7 [–5.2 to –0.3], p5 .030).
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In addition, high test–retest reliability for a 2-week period
could be largely demonstrated, except for SP-D, which
may be explained by inconsistent contact with the phobic
situation or object at the 2 points of measurement.
Similarly, ratings of specific phobic situations might be
inexact in cases with more than one phobia, caused by a
lack of reference to one specific and concrete situation.4
In Study 2, and despite rather low case numbers,
sensitivity to change approximately 1 year after initial
assessment was found significant for the dimensional
scales PD-D, GAD-D, and Cross-D, and trends for SAD-D,
SP-D and AG-D emerged.
Expanding previous studies, we also included the PAS
and FSS-III in Study 1 to account for the severity of
panic disorder and agoraphobia as well as a broader
spectrum of specific fears. In previous investigations,
validity of the respective dimensional scales was
demonstrated, but was modest, particularly for SP-D.
Concurrent and discriminant validity was supported for
AG-D and PD-D, but remained poor for SP-D—even
when alternative validity measures covering the blood/
injury and the animal subtype of specific phobia were
considered. Hence, poor validity for the SP-D scale
may be explained by imprecise introduction and/or item
formulation. For AG-D, concurrent validity was sup-
ported using the PAS and FSS-Agoraphobia subscale
as alternative validity measures. Of note, correlations
of AG-D were highest for BSI phobia, PAS and FSS-
Agoraphobia, questioning the FQ-Agoraphobia as a
validity measure in a nonclinical sample.
From the variety of validity measures, future studies
should however consider which scales to use to investi-
gate the psychometric properties, acknowledging time
constraints and motivation of participants. Our studies
indicate preference of the Mini-SPIN against the FSS-III
for SAD-D, the BSI phobia, PAS, or FSS-III over the
FQ-Agoraphobia for AG-D, the BSI anxiety or PAS for
PD-D, and the GAD-7 for GAD-D. We further suggest
carefully considering use of the FSS-III because of its
length, and because results did not turn out to be
superior to other validity measures. For SP-D, validity
needs to be further evaluated, probably regarding both
item formulation and selection of validity measures.
To also investigate the dimensional scales’ sensitivity
to change, a subsample of adult attendees to a German
outpatient clinic4 was re-examined approximately 1 year
after initial assessment. Evidence was found at least for
PD-D, GAD-D, and Cross-D. Nevertheless, confidence
intervals were relatively narrow despite fairly small
sample sizes, tentatively suggesting underlying effects
despite failed significance for SAD-D, SP-D, and AG-D.
Overall utility of the Cross-D as a more brief cross-
cutting measure has been difficult to evaluate so far.
One study observed insufficient correlations between
disorder-specific scales and Cross-D,3 while others4
found moderate to high correlations to the disorder-
specific scales. Study 1 thus re-examined psychometric
properties of the Cross-D, demonstrating again con-
current validity of the Cross-D because of its correla-
tions with disorder-specific scales (except for SP-D) and
with the PROMIS-Anx. However, correlations between
Cross-D and dimensional scales ranged between .60 for
AG-D and .84 for PD-D, suggesting that the Cross-D
may be more related to some anxiety disorders than to
others. If so, then use of the Cross-D as an independent
measure across the anxiety disorders would be proble-
matic. The Cross-D was, however, the only scale to
differentiate between probable cases with and without
help-seeking. Also, test–retest reliability and sensitivity
to change was as good for the Cross-D as for the
dimensional anxiety scales, arguing for its clinical utility
at least on a broad level (ie, any anxiety disorder).
Of note, dimensional anxiety measures have been used
for decades to reflect the frequency, severity, or variety of
symptoms, thereby accounting for the dimensional nature
of the underlying psychological phenomena.2,31,32 From
that, one may ask why should we put so much emphasis
on the dimensional anxiety scales for DSM-5? Is it not just
simply a repetition of what is already known? Broadly
speaking, this new dimensional approach is highly of
interest for clinical practice, because it assesses symptoms
of disorders nearer to their real nature of psychopatho-
logy. More precisely, the major advantages of the ‘‘new’’
scales are that they are brief, concise, and based on a
consistent template to measure the multiple symptoms of
fear and anxiety, covering cognitive, physiological, and
behavioral aspects, across a range of diagnostic con-
structs. In particular for respondents with more than one
anxiety disorder, which is the rule in the majority of cases,
the scales may facilitate assessment by reflecting what
kind of symptoms are present for which anxiety disorder
and to what degree.
The strengths of our approach include the recruit-
ment and reassessment of a relatively large student
and clinical sample for psychometric and test–retest
evaluation of the dimensional scales, demonstrating
applicability of the scales also in online surveys, and the
application of widely used self-report measures for
validation purposes. Drop-out analyses revealed that
differences between respondents who participated at
Time 1 only in contrast to those participating at both
assessments did not affect findings in either study.
Our findings need, however, to be considered with
regard to some caveats. In both studies, participants were
relatively young, well educated, and single, which limits
generalizability of results to older or less educated
samples. There was a preponderance of females in both
samples. Given epidemiological and frequent clinical
observations that females are more often affected than
males by anxiety disorders, and that anxiety disorders are
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more disabling in females than in males in terms of
comorbidity patterns and illness burden,33 our sample and
study findings likely map relations in clinical practice,
without necessarily limiting generalizability of our find-
ings. Comorbidity was not evaluated here. However, most
recent findings on the dimensional anxiety scales’
sensitivity to clinical severity indicated that self-reports
of adult patients were largely unaffected by the number of
anxiety disorders or depressive disorders.6
In Study 1 (student sample), we used the SSQ to
screen for the probable diagnostic status. The SSQ is part
of the DIA-X/M-CIDI,9 for which reliable and valid
assessment of mental disorders was established.34,35
Acknowledging the limits of screening inventories,14
help-seeking was considered to indicate severity or
impairment due to (probable) diagnostic status. However,
as this may have limited group sizes for comparisons of
disorder-specific dimensional scales and the Cross-D for
participants with vs without an indication for anxiety
disorder, help-seeking did not validate caseness.
In Study 2, the low response rate of 53.9% (55/102
participants) at second assessment resulted in a small
sample size available for analyses, particularly concern-
ing specific diagnoses. Analyses with more statistical
power might have yielded more significant findings.
Diagnoses are limited to self-report and clinician
ratings. Measurement of change is based on patient’s
self ratings, which may be subject to bias. Clinicians’
ratings of change were not available for all patients
for the exact time of dimensional scale reassessment.
In addition, the most optimal design to evaluate the
scales’ sensitivity to change would require including
a non-treated comparison group,36 which was not
feasible in our study. Future studies should therefore
include objective change ratings that are related to
actual diagnoses and replicate analyses in larger samples
when examining the dimensional scales’ sensitivity
to change.
Conclusion
Good psychometric properties of the brief, consistent,
and generally formulated dimensional anxiety scales for
DSM-5 have been established in terms of unidimension-
ality, convergent and discriminant validity, classification
performance, and sensitivity to clinical severity. Using a
larger sample of students and reassessment of a clinical
sample, these most recent studies replicate previous
findings and, in addition, demonstrate high test–retest
reliability and sensitivity to change. Hence, evidence
from different samples (students vs clinical sample)
and across different ages (young vs middle-age adults)
increases for the clinical utility of the dimensional
anxiety scales in clinical settings and relative fields (ie,
prospective observations). However, revision of SP-D for
the assessment of specific phobias is implied given the
modest validity and reliability. For the Cross-D, there is
similar evidence for its clinical utility, its sensitivity to
change, and the utility of the Cross-D as an instrument
to assess anxiety disorders, although further evaluation
concerning beneficial effects beyond the specific dimen-
sional scales is implied. Overall, these findings strongly
argue for the use of the new dimensional anxiety scales
for routine use in clinical practice.
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